August is SMA Awareness Month, and advocates around the world are gearing up to raise awareness about spinal muscular…
Marisa Horak, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Horak, MS
A community-driven campaign called SMAshing My Limits And Going Places aims to make it easier for people with spinal…
An official decision on whether to approve apitegromab for spinal muscular atrophy (SMA) in the European Union may hinge…
England is rolling out newborn screening for spinal muscular atrophy (SMA), which will allow all babies born in the…
The spinal muscles of spinal muscular atrophy (SMA) patients who also have scoliosis show abnormalities in molecular activity, particularly in…
A woman with spinal muscular atrophy (SMA) who has become a champion for those living with disabilities — as…
The one-time gene therapy Itvisma (onasemnogene abeparvovec-brve) is now approved in the European Union for people with spinal…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to salanersen, a new, more potent…
Spinraza (nusinersen) is able to help slow lung function decline in people with spinal muscular atrophy (SMA), even…
The U.S. Food and Drug Administration (FDA) is expected to decide in the coming months whether or not to approve…